Molecure S.A. (MOC.WA)

PLN 10.0

(-1.96%)

Net Income Summary of Molecure S.A.

Molecure S.A.'s latest annual net income in 2023 was -18.3 Million PLN , down -35.22% from previous year.
Molecure S.A.'s latest quarterly net income in 2024 Q3 was -6.26 Million PLN , up 18.93% from previous quarter.
Molecure S.A. reported an annual net income of -13.53 Million PLN in 2022, up 0.75% from previous year.
Molecure S.A. reported an annual net income of -13.64 Million PLN in 2021, down -120.07% from previous year.
Molecure S.A. reported a quarterly net income of -7.72 Million PLN for 2024 Q2, down -12.97% from previous quarter.
Molecure S.A. reported a quarterly net income of -6.83 Million PLN for 2024 Q1, down -0.53% from previous quarter.

Annual Net Income Chart of Molecure S.A. (2023 - 2015)

Historical Annual Net Income of Molecure S.A. (2023 - 2015)

Year	Net Income	Net Income Growth
2023	-18.3 Million PLN	-35.22%
2022	-13.53 Million PLN	0.75%
2021	-13.64 Million PLN	-120.07%
2020	67.96 Million PLN	1700.31%
2019	-4.24 Million PLN	-12.43%
2018	-3.77 Million PLN	-57.1%
2017	-2.4 Million PLN	0.82%
2016	-2.42 Million PLN	-333.6%
2015	-559.1 Thousand PLN	0.0%

Year	Net Income	Net Income Growth
2024 Q3	-6.26 Million PLN	18.93%
2024 Q2	-7.72 Million PLN	-12.97%
2024 Q1	-6.83 Million PLN	-0.53%
2023 Q2	-4.12 Million PLN	-85.07%
2023 FY	-18.3 Million PLN	-35.22%
2023 Q3	-4.14 Million PLN	-0.53%
2023 Q4	-6.8 Million PLN	-64.12%
2023 Q1	-2.22 Million PLN	63.3%
2022 Q2	-3.47 Million PLN	-6.78%
2022 Q4	-6.07 Million PLN	-303.45%
2022 FY	-13.53 Million PLN	0.75%
2022 Q1	-3.25 Million PLN	52.14%
2022 Q3	-1.5 Million PLN	56.74%
2021 Q4	-6.8 Million PLN	-262.43%
2021 FY	-13.64 Million PLN	-120.07%
2021 Q3	-1.87 Million PLN	33.14%
2021 Q2	-2.8 Million PLN	-31.26%
2021 Q1	-2.13 Million PLN	-103.22%
2020 Q2	-463.99 Thousand PLN	46.78%
2020 Q3	-750.5 Thousand PLN	-61.75%
2020 Q4	66.36 Million PLN	8942.19%
2020 FY	67.96 Million PLN	1700.31%
2020 Q1	-871.89 Thousand PLN	32.58%
2019 Q1	-1.24 Million PLN	31.21%
2019 Q4	-1.29 Million PLN	-49.8%
2019 Q3	-863.24 Thousand PLN	-13.05%
2019 Q2	-763.6 Thousand PLN	38.7%
2019 FY	-4.24 Million PLN	-12.43%
2018 Q4	-1.81 Million PLN	-161.96%
2018 Q2	-1.38 Million PLN	-147.69%
2018 Q1	-559.9 Thousand PLN	64.57%
2018 FY	-3.77 Million PLN	-57.1%
2018 Q3	-691.26 Thousand PLN	50.16%
2017 Q1	-473.25 Thousand PLN	73.14%
2017 Q4	-1.58 Million PLN	-2424.28%
2017 FY	-2.4 Million PLN	0.82%
2017 Q3	-62.6 Thousand PLN	78.27%
2017 Q2	-288.14 Thousand PLN	39.11%
2016 Q3	-51.61 Thousand PLN	83.09%
2016 Q4	-1.76 Million PLN	-3314.28%
2016 FY	-2.42 Million PLN	-333.6%
2016 Q1	-305.27 Thousand PLN	0.0%
2016 Q2	-305.27 Thousand PLN	0.0%
2015 FY	-559.1 Thousand PLN	0.0%

Peer Net Income Comparison of Molecure S.A.

Name	Net Income	Net Income Difference
Bioceltix S.A.	-13.68 Million PLN	-33.758%
BIOTON S.A.	2.27 Million PLN	904.756%
Captor Therapeutics Spolka Akcyjna	-70.58 Million PLN	74.062%
Mabion S.A.	41.26 Million PLN	144.363%
NanoGroup S.A.	-7.88 Million PLN	-132.048%
Pharmena S.A.	28.94 Million PLN	163.26%
Poltreg S.A.	-13.55 Million PLN	-35.106%
Pure Biologics Spólka Akcyjna	-35.69 Million PLN	48.708%
Ryvu Therapeutics S.A.	-92.11 Million PLN	80.124%
Synthaverse S.A.	4.75 Million PLN	484.788%
Urteste S.A.	-5.58 Million PLN	-227.752%